

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4775142

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	ORAGENICS, INC.	06/24/2016
RECEIVING PARTY DATA		
Name:	PROBIORA HEALTH, LLC	
Street Address:	3525 TURTLE CREEK BLVD, 19B	
City:	DALLAS	
State/Country:	TEXAS	
Postal Code:	75219	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	15582429
CORRESPONDENCE DATA		
Fax Number:	(949)943-8358	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	949-943-8300	
Email:	tlightman@fishiplaw.com	
Correspondent Name:	FISH IP LAW, LLP	
Address Line 1:	2603 MAIN STREET, SUITE 1000	
Address Line 4:	IRVINE, CALIFORNIA 92614	
ATTORNEY DOCKET NUMBER:	102978.0002US2	
NAME OF SUBMITTER:	ROBERT D. FISH	
SIGNATURE:	/Robert D. Fish/	
DATE SIGNED:	01/12/2018	
Total Attachments: 17		
source=Assignment, fully executed#page1.tif		
source=Assignment, fully executed#page2.tif		
source=Assignment, fully executed#page3.tif		
source=Assignment, fully executed#page4.tif		
source=Assignment, fully executed#page5.tif		
source=Assignment, fully executed#page6.tif		

source=Assignment, fully executed#page7.tif
source=Assignment, fully executed#page8.tif
source=Assignment, fully executed#page9.tif
source=Assignment, fully executed#page10.tif
source=Assignment, fully executed#page11.tif
source=Assignment, fully executed#page12.tif
source=Assignment, fully executed#page13.tif
source=Assignment, fully executed#page14.tif
source=Assignment, fully executed#page15.tif
source=Assignment, fully executed#page16.tif
source=Assignment, fully executed#page17.tif

ASSIGNMENT OF INTELLECTUAL PROPERTY

THIS ASSIGNMENT OF INTELLECTUAL PROPERTY ("**Assignment**"), made as of this 24th day of June, 2016 (the "**Effective Date**"), is by and between Oragenics, Inc., a Florida corporation ("**Assignor**"), and ProBiora Health, LLC a Delaware limited liability company ("**Assignee**").

WITNESSETH:

WHEREAS, Assignor, Assignee, and Christine L. Koski have entered into that certain Asset Purchase Agreement, dated June 22, 2016 (the "**Asset Purchase Agreement**") pursuant to which Assignee purchased certain assets and liabilities of Assignor used in Assignor's over-the-counter oral probiotic business; and

WHEREAS, Assignor is the sole and exclusive owner of all right, title and interest in and to the Intellectual Property (as defined in the Asset Purchase Agreement), including but not limited to those (i) patents and patent applications set forth on Exhibit A, and (ii) trademark registrations and applications set forth in Exhibit B hereto; unregistered copyright works identified in Exhibit C; trade secrets identified in Exhibit D; and miscellaneous intellectual property identified in Exhibit E.

WHEREAS, under the terms of the Asset Purchase Agreement, Assignor has conveyed, transferred and assigned to Assignee, among other assets, the Intellectual Property, and has agreed to execute and deliver this Assignment, for recording with the United States Patent and Trademark Office, the United States Copyright Office, and corresponding entities or agencies in any applicable jurisdictions.

NOW, THEREFORE, for the consideration recited in the Asset Purchase Agreement and the premises, agreements, covenants and provisions contained herein, as well as other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor and Assignee hereby agree as follows:

1. Assignor hereby confirms that it irrevocably sells, assigns, transfers and delivers to Assignee its entire right, title and interest in and to the Intellectual Property, including the Intellectual Property more specifically set forth below, and Assignee hereby accepts all of Assignor's right, title and interest in and to such Intellectual Property.

PATENT

2. With respect to the patent rights identified in Exhibit A and the corresponding inventive subject matters, (the "**Patent Rights**"), Assignor irrevocably transfers, conveys and assigns to Assignee, its successors and assigns, in perpetuity, the entire title, right and interest in and to the inventive subject matters, and to all Letters Patent or similar legal protection arising therefrom, not only in the United States and its territorial possessions, but in all countries foreign thereto to be obtained for said inventive subject matters by said applications or any continuations, continuations-in-part, divisionals, renewals, substitutes, reissues or reexaminations thereof, or

any legal equivalent thereof in any foreign country(ies) for the full term or terms for which the same may be granted, including all priority rights under any International Convention.

3. Also with respect to the Patent Rights, Assignor irrevocably transfers, conveys and assigns to Assignee, its successors and assigns, in perpetuity, (a) all common law rights related thereto; and (b) all benefits, privileges, causes of action and remedies relating to any of the foregoing, whether before or hereafter accrued, including without limitation the exclusive rights to apply for and maintain all such registrations, renewals and/or extensions thereof, to sue for all past, present or future infringements or other violations of any rights thereof, and to settle and retain proceeds from any such actions.

TRADEMARK

4. With respect to the marks identified in Exhibit B, including any renewals or extensions thereto (the “**Marks**”), Assignor irrevocably transfers, conveys and assigns to Assignee, its successors and assigns, in perpetuity, (a) all right, title and interest, including all goodwill appurtenant thereto; (b) all common law rights related thereto; and (c) all benefits, privileges, causes of action and remedies relating to any of the foregoing, whether before or hereafter accrued, including without limitation the exclusive rights to apply for and maintain all such registrations, renewals and/or extensions thereof, to sue for all past, present or future infringements or other violations of any rights thereof, and to settle and retain proceeds from any such actions.

5. Assignee retains no rights to use any of the Marks, agrees to not to challenge the validity of Assignee's ownership in the Marks.

COPYRIGHT

6. With respect to the works identified in Exhibit C, including any renewals or extensions thereto (collectively the “**Works**”), Assignor irrevocably transfers, conveys and assigns to Assignee, its successors and assigns, in perpetuity, (a) all right, title and interest; (b) all common law rights related thereto; and (c) all benefits, privileges, causes of action and remedies relating to any of the foregoing, whether before or hereafter accrued, including without limitation the exclusive rights to apply for and maintain all such registrations, renewals and/or extensions thereof, to sue for all past, present or future infringements or other violations of any rights thereof, and to settle and retain proceeds from any such actions.

7. Assignor retains no rights to use any of the Works, and agrees not to challenge the validity of Assignee's ownership in the Works.

8. Assignor hereby waives any moral rights under any U.S. or International copyright law that it may have in any of the Works.

TRADE SECRET

9. Assignor irrevocably transfers, conveys and assigns to Assignee, its successors and assigns, in perpetuity, any and all of the trade secrets identified in Exhibit D.

MISCELLANEOUS INTELLECTUAL PROPERTY

10. Assignor irrevocably transfers, conveys and assigns to Assignee, its successors and assigns, in perpetuity, any and all of the miscellaneous Intellectual Property identified in identified in Exhibit E.
11. As to the domains listed in Exhibit E as being owned by "Domains by Proxy", Assignor will promptly assign the domains to Assignee by performing all commercially reasonable steps required to effect the transfers, including logging into Assignor's customer account at Domains by Proxy, and initiating an "Account Change" in favor of Assignee.
12. Assignor agrees not to obstruct Assignee's efforts to register EVORAPETOFFER.COM.

MISCELLANEOUS TERMS

13. Corporate Authority. Each of the corporate Parties represents and warrants that:
- 13.1. It is a corporation that is validly existing and in good standing under the laws of the jurisdiction in which it is organized;
 - 13.2. It has full corporate power to execute, deliver and perform its obligations under this Assignment; and
 - 13.3. The person executing this Agreement on its behalf has its full authority to do so.
14. No Conflict. Assignor hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.
15. Cooperation. Assignor shall execute such written instruments, extend such other cooperation and perform such other acts as may be necessary or appropriate, in the opinion of Assignee, to convey, establish, evidence, maintain, defend and enforce Assignee's rights in the Intellectual Property, and Assignor hereby irrevocably appoints Assignee and any of its officers as Assignor's attorney in fact to undertake such acts in Assignor's name.
16. Reliance. Assignor acknowledges that Assignee is relying upon Assignor's representations, warranties, covenants, agreements and indemnities made in the Asset Purchase Agreement with respect to the Intellectual Property as an inducement to entering into this Assignment. The representations, warranties, covenants, agreements and indemnities contained in the Asset Purchase Agreement shall not be superseded hereby but shall remain in full force and effect to the full extent provided therein.
17. Notices. All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be deemed to have been given (a) when delivered by hand (with written confirmation of receipt); (b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by facsimile or e-mail of a PDF document (with confirmation of transmission) if sent during normal business hours of the recipient, and on the next business day if sent after normal business hours of the recipient; or (d) on the third day after the date mailed, by certified or registered mail, return receipt requested,

postage prepaid. Such communications must be sent to the respective Parties at the following addresses (or at such other address for a Party):

If to Assignee:

Oragenics, Inc.
4902 Eisenhower Boulevard, Suite 125
Tampa, FL 33634
Attn: Michael Sullivan, CFO

with a copy, which shall not constitute notice, to:
Mark A. Catchur, Esq.
Shumaker, Loop & Kendrick LLP
101 East Kennedy Blvd., Suite 2800
Tampa, FL 33602
mcatchur@slk-law.com

If to Assignee:

ProBiora Health, LLC
3824 Cedar Springs Rd., #349
Dallas, TX 75219
Attn: Christine L. Koski, Manager
ckoski@probiorahealth.net

with a copy, which shall not constitute notice, to:
Louis T. M. Conti, Esq.
Holland & Knight LLP
100 North Tampa Street, Suite 4100
Tampa, Florida 33602
louis.conti@hklaw.com

18. Construction. Whenever the words "include," "includes" or "including" are used in this Agreement, they shall be deemed to be followed by the words "without limitation."

19. Severability. If any term or provision of this Assignment is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Assignment or invalidate or render unenforceable such term or provision in any other jurisdiction.

20. Costs and Fees. In the event that any legal proceedings arise as a result of this Assignment, the prevailing party is entitled to receive attorney fees.

21. Time of the Essence. Time is of the essence in this Assignment.

22. Failure to Enforce. Failure of any Party herein to enforce any of the terms of this Assignment shall not constitute waiver to enforce that term in the future.

23. Entire Agreement. In conjunction with terms set forth in the Asset and Purchase Agreement, this Assignment and the documents to be delivered hereunder constitute the sole and entire agreement of the Parties to the subject matter contained herein, and supersedes all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter.

24. Successors and Assigns. This Assignment shall be binding upon and shall inure to the benefit of the Parties hereto and their respective successors and permitted assigns. Neither Party may assign its rights or obligations hereunder without the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed. No assignment shall relieve the assigning Party of any of its obligations hereunder.

25. Amendment and Modification. This Assignment may only be amended, modified or supplemented by an Assignment in writing signed by each Party hereto.

26. Waiver. No waiver by any Party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the Party so waiving. No waiver by any Party shall operate or be construed as a waiver in respect of any failure, breach or default not expressly identified by such written waiver, whether of a similar or different character, and whether occurring before or after that waiver. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Assignment shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.

27. Gender. Where appropriate, the singular number set forth in this Assignment shall be interpreted as the plural number, and the gender shall be interpreted as masculine, feminine or neuter, as the context dictates.

28. Relationship Of Parties. This Assignment does not constitute or create a joint venture, partnership, agency relationship, or formal business organization of any kind, and the rights and obligations of the Parties shall be those of independent contractors only.

29. Governing Law. This Assignment shall be governed by and construed in accordance with the internal laws of the State of Florida without giving effect to any choice or conflict of law provision or rule (whether of the State of Florida or any other jurisdiction).

30. Submission to Jurisdiction. Any legal suit, action or proceeding arising out of or based upon this Assignment or the transactions contemplated hereby may be instituted in the federal courts of the United States of America or the courts of the State of Florida in each case located in the city of Tampa and county of Hillsborough, and each Party irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action or proceeding.

31. Waiver of Jury Trial. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS ASSIGNMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL ACTION ARISING OUT OF OR

RELATING TO THIS ASSIGNMENT OR THE TRANSACTIONS CONTEMPLATED
HEREBY.

32. Specific Performance. The Parties agree that irreparable damage would occur if any provision of this Assignment were not performed in accordance with the terms hereof and that the Parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy to which they are entitled at law or in equity.

33. Representation by Counsel. Each of the Parties hereto acknowledges that it has had the opportunity to be represented by independent legal counsel of its own choice throughout all of the negotiations that preceded the execution of this Assignment and that each has executed this Assignment with the consent and on the advice of any such independent legal counsel; and further acknowledges that it and any such counsel have had an adequate opportunity to make whatever investigation or inquiry they may deem necessary or desirable in connection with any of the subjects of this Assignment prior to the execution hereof.

34. Counterparts. This Assignment may be executed in counterparts, each of which shall be deemed an original, and all of which, when taken together, will be deemed to constitute one and the same Assignment. A signed copy of this Assignment delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Assignment.

[Remainder of Page Intentionally Left Blank; Signature Page Follows]

IN WITNESS WHEREOF, Assignor and Assignee have caused this Assignment to be executed on the day first written above.

ASSIGNOR:

Oragenics, Inc.,
a Florida corporation

By: 

Name: Michael Sullivan
Title: Chief Financial Officer

ASSIGNEE:

ProBiora Health, LLC,
a Delaware limited liability company

By: _____

Name: Christine L. Koski
Title: Manager

[Signature Page to Assignment of Intellectual Property]

IN WITNESS WHEREOF, Assignor and Assignee have caused this Assignment to be executed on the day first written above.

ASSIGNOR:

Oragenics, Inc.,
a Florida corporation

By: _____
Name: Michael Sullivan
Title: Chief Financial Officer

ASSIGNEE:

ProBiora Health, LLC,
a Delaware limited liability company

By: Christine L. Koski
Name: Christine L. Koski
Title: Manager

[Signature Page to Assignment of Intellectual Property]

EXHIBIT A**PATENTS & APPLICATIONS**

MBHB Case Number and Country	Serial Number & Filing Date	Title of Application	Status
Probiora3®			
02-1037 US US	60/494169 8-11-2003	Compositions and Methods for the Maintenance of Oral Health	Inactive
02-1037-I US	10/567592 6/30/06	Compositions and Methods for the Maintenance of Oral Health	Granted; U.S. Pat. No. 7,931,892
02-1037-I-DIV US	13/017214 1/31/11	Compositions and Methods for the Maintenance of Oral Health	Granted; U.S. Pat. No. 8,865,156
02-1037-I-CON US	14/518,226 10/20/14	Compositions and Methods for the Maintenance of Oral Health	Pending
02-1037-A PCT	US04/025899 WO05/018342 8-10-2004	Compositions and Methods for the Maintenance of Oral Health	National phase entered.
02-1037-B Australia	2004266615 8-10-2004	Compositions and Methods for the Maintenance of Oral Health	Granted; Pat. No. 2004266615 Annuity due 8/10/16 \$842 ¹
02-1037-C Canada	2535764 8-10-2004	Compositions and Methods for the Maintenance of Oral Health	Granted; Pat. No. 2535764 Annuity due 8/10/16 \$528
02-1037-D China	200480029485 8-10-2004	Compositions and Methods for the Maintenance of Oral Health	Abandoned September 2011
02-1037-D-DIV China	201110291647.0 8-10-2004	Compositions and Methods for the Maintenance of Oral Health	Abandoned March 2013
02-1037-D-DIV-HK Hong Kong	12109152.1 9/18/2012	Compositions and Methods for the Maintenance of Oral Health	Abandoned March 2013
02-1037-E Europe	04780692.2 8-10-2004	Compositions and Methods for the Maintenance of Oral Health	Granted Pat. No. 1659885

¹ Annuity payment amounts are estimates.

MBHB Case Number and Country	Serial Number & Filing Date	Title of Application	Status
02-1037-E-BE Belgium	Pat. No. 1659885	Compositions and Methods for the Maintenance of Oral Health	Granted Annuity due 8/10/16 \$757
02-1037-E-DK Denmark	Pat. No. 1659885	Compositions and Methods for the Maintenance of Oral Health	Granted Annuity due 8/10/16 \$934
02-1037-E-FI Finland	Pat. No. 1659885	Compositions and Methods for the Maintenance of Oral Health	Granted Annuity due 8/10/16 \$1088
02-1037-E-FR France	Pat. No. 1659885	Compositions and Methods for the Maintenance of Oral Health	Granted Annuity due 8/10/16 \$850
02-1037-E-DE Germany	Pat. No. 1659885	Compositions and Methods for the Maintenance of Oral Health	Granted Annuity due 8/10/16 \$1364
02-1037-E-IE Ireland	Pat. No. 1659885	Compositions and Methods for the Maintenance of Oral Health	Granted Annuity due 8/10/16 \$769
02-1037-E-IT Italy	Pat. No. 1659885	Compositions and Methods for the Maintenance of Oral Health	Granted Annuity due 8/10/16 \$1085
02-1037-E-LU Luxembourg	Pat. No. 1659885	Compositions and Methods for the Maintenance of Oral Health	Granted Annuity due 8/10/16 \$655
02-1037-E-NL Netherlands	Pat. No. 1659885	Compositions and Methods for the Maintenance of Oral Health	Granted Annuity due 8/10/16 \$1288
02-1037-E-PL Poland	Pat. No. 1659885	Compositions and Methods for the Maintenance of Oral Health	Granted Annuity due 8/10/16 \$901
02-1037-E-ES Spain	Pat. No. 1659885	Compositions and Methods for the Maintenance of Oral Health	Granted Annuity due 8/10/16 \$877
02-1037-E-SE Sweden	Pat. No. 1659885	Compositions and Methods for the Maintenance of Oral Health	Granted Annuity due 8/10/16 \$941
02-1037-E-CH Switzerland	Pat. No. 1659885	Compositions and Methods for the Maintenance of Oral Health	Granted Annuity due 8/10/16 \$1051
02-1037-E-TR	Pat. No. 1659885	Compositions and	Granted

MBHB Case Number and Country	Serial Number & Filing Date	Title of Application	Status
Turkey		Methods for the Maintenance of Oral Health	Annuity due 8/10/16 \$790
02-1037-E-GB Great Britain	Pat. No. 1659885	Compositions and Methods for the Maintenance of Oral Health	Granted Annuity due 8/10/16 \$822
02-1037-F Japan	2006-53306 8-10-2004	Compositions and Methods for the Maintenance of Oral Health	Abandoned September 2011
02-1037-F-DIV Japan	2011-207299 9-22-2011	Compositions and Methods for the Maintenance of Oral Health	Abandoned November 2013
02-1037-G S. Korea	2006-7002806 8-10-2004	Compositions and Methods for the Maintenance of Oral Health	Granted Pat. No. 10-1176660 Annuity due 8/17/16 \$891
02-1037-H New Zealand	545730 8-10-2004	Compositions and Methods for the Maintenance of Oral Health	Granted 545730
Tooth Whitening			
07-1212 US	61/061,264 6-13-08	Use of Hydrogen-Peroxide Bacteria for Tooth Whitening	Expired
07-1212-US US	12/482,881 6-11-09	Use of Hydrogen-Peroxide Bacteria for Tooth Whitening	Pending
07-1212-WO PCT	PCT/US09/047040 6-11-09	Use of Hydrogen-Peroxide Bacteria for Tooth Whitening	National Phase entered
07-1212-WO-AU Australia	2009257440 6-11-09	Use of Hydrogen-Peroxide Bacteria for Tooth Whitening	Granted; 2009257440 Annuity due 6/11/16 \$670
07-1212-WO-CA Canada	2727462 6-11-09	Use of Hydrogen-Peroxide Bacteria for Tooth Whitening	Pending; Annuity due 6/11/16 \$793
07-1212-WO-CN China	200980131840.9 6-11-09	Use of Hydrogen-Peroxide Bacteria for Tooth Whitening	Abandoned Feb. 2016 in favor of 20161065409.0
07-1212-WO-CN China	20161065409.0 6-11-09	Use of Hydrogen-Peroxide Bacteria for Tooth Whitening	Pending
07-1212-WO-HK Hong Kong	121004313 1-13-12	Use of Hydrogen-Peroxide Bacteria for Tooth Whitening	Pending
07-1212-WO-EP Europe	09763620.3 6-11-09	Use of Hydrogen-Peroxide Bacteria for Tooth Whitening	Allowed; Text for grant, grant and printing fees, and claim translations due

MBHB Case Number and Country	Serial Number & Filing Date	Title of Application	Status
			to be paid 8/5/16; Annuity due 6/11/16 \$2014
07-1212-WO-JP Japan	2011-513687 6-11-09	Use of Hydrogen- Peroxide Bacteria for Tooth Whitening	Abandoned December 2014
07-1212-WO-KR Korea	10-2011-7029892 6-11-09	Use of Hydrogen- Peroxide Bacteria for Tooth Whitening	Abandoned April 2014
07-1212-WO-MX Mexico	MX/a/2010/013847 6-11-09	Use of Hydrogen- Peroxide Bacteria for Tooth Whitening	Granted; 328690
07-1212-WO-MX-DIV Mexico	MX/a/2013/007321 6-21-13	Use of Hydrogen- Peroxide Bacteria for Tooth Whitening	Pending
07-1212-WO-NZ New Zealand	590348 6-11-09	Use of Hydrogen- Peroxide Bacteria for Tooth Whitening	Granted Pat. No. 590348 Annuity due 6/11/16 \$491

EXHIBIT B**TRADEMARK APPLICATIONS & REGISTRATIONS**

MBHB Case Number	Serial Number & Filing Date	Trademark	Status
08-1019 US	77/565,874 9/9/08	PROBIORA	Abandoned
08-1020 US	77/565,838 9/9/08	EVORA	Abandoned
08-1020-AU Australia	Unfiled	EVORA	Abandoned
08-1020-AR Argentina	3124889 10/27/11	EVORA	Pending
08-1020-BR Brazil	840014023 2/1/12	EVORA	Pending
08-1020-CL Chile	985868 12/28/11	EVORAPLUS & design	Registered 1014051 6/6/13
08-1020-JP Japan	2011-85965 11/30/11	EVORA	Registered 5529020 10/19/12
08-1020-MX Mexico	1210545 9/9/11	EVORA	Abandoned
08-1020-NZ New Zealand	Unfiled	EVORA	Abandoned
08-1020-PE Peru	465224 8/23/11	EVORA	Abandoned
08-1020-VE Venezuela	2421-2012 2/10/12	EVORA	Registered 2421-2012 12/18/12
08-1057 US	77/565,843 9/9/08	EVORAPLUS	Registered 3747523 2/9/10
08-1057-AU Australia	1434956 7/4/11	EVORAPLUS	Registered 1434956 7/4/11
08-1057-MX Mexico	1269857 4/27/12	EVORAPLUS	Registered 1315106 9/27/12
08-1057-NZ New Zealand	845099 7/4/11	EVORAPLUS	Registered 845099 4/4/11
08-1057-TW Taiwan	100028484 6/8/11	EVORAPLUS	Registered 01535744 9/16/12
08-1057-TW2 Taiwan	100028487 6/8/11	EVORAPLUS & Design	Registered 01535745 9/16/12
08-1058 US	77/565,847 9/9/08	EVORAPRO	Registered 3883393 11/30/10
08-1058-MX Mexico	13111914 9/25/12	EVORAPRO	Registered 1345590 1/30/13
08-1082 US	77/565,856 9/9/08	EVORAPET	Abandoned
08-1082-US US	86/386,460	EVORAPET	Registered 4806890 09/08/15
08-1082-CA Canada	1562888 2/16/12	EVORAPET	Registered 1562888 7/17/13
08-1082-MX Mexico	1311929 9/25/12	EVORAPET	Registered 1340679 12/19/12
08-1082-JP Japan	2012-9308 2/10/12	EVORAPET	Registered 5560344 2/22/13

08-1083 US	77/565,861 9/9/08	EVORAKIDS	Registered 3873950 11/9/10
08-486 US	77/565,877 9/9/08	PROBIORA3	Registered 3747524 2/9/10
08-486-AR Argentina	3110268 8/28/11	PROBIORA3	Registered 2541837 11/30/12
08-486-AU Australia	1434957 7/4/11	PROBIORA3	Registered 1434957 7/4/11
08-486-BR2 Brazil	840019157 2/6/12	PROBIORA3 and design	Registered 840019157 3/31/15
08-486-CL Chile	969767 9/13/11	PROBIORA3	Registered 1059907 11/25/13
08-486-EM Europe	8142424 3/6/09	PROBIORA3	Registered 8142424 11/11/09
08-486-JP Japan	2012-9311 2/10/12	PROBIORA3	Registered 5560345 2/22/13
08-486-KR2 Korea	40-2011-69964 12/12/11	PROBIORA3	Registered 40-953309 2/13/13
08-486-MX Mexico	1215905 9/29/11	PROBIORA3	Registered 1270171 2/22/12
08-486-NZ New Zealand	845099 7/4/11	PROBIORA3	Registered 845100 7/4/11
08-486-PE Peru	465225 8/23/11	PROBIORA3	Registered 183031 12/27/11
08-486-TW Taiwan	100028819 6/9/11	PROBIORA3	Registered 1512729 4/16/12
08-486-VE Venezuela	2422-2012 2/10/12	PROBIORA3	Registered 2422-2012 12/18/12
09-276 US	77/858,544 10/27/09	TEDDY'S PRIDE	Registered 3806461 6/22/10
09-276-AU Australia	1434960 7/4/11	TEDDY'S PRIDE	Registered 1434960 7/4/11
09-276-KR2 Korea	40-2011-69965 12/12/11	TEDDY'S PRIDE	Pending
09-276-NZ New Zealand	845101 7/4/11	TEDDY'S PRIDE	Registered 845101 7/4/11
09-276-ZA South Africa	2011/28125 11/4/11	TEDDY'S PRIDE	Registered 2011/28125 10/25/13
10-947	85/466150 11/7/11	STREPTOCOCCUS RATTUS JH145	Registered 4174724 7/17/12
10-948	85/466139 11/7/11	STREPTOCOCCUS UBERIS KJ2	Registered 4174723 7/17/12
10-949	85/466154 11/7/11	STREPTOCOCCUS ORALIS KJ3	Registered 4174725 7/17/12

EXHIBIT C

COPYRIGHT

- 1) All advertising materials pertaining to the ProBiora3 Business (as defined in the Asset Purchase Agreement)
- 2) All instructional materials, include package inserts pertaining to the ProBiora3 Business (as defined in the Asset Purchase Agreement)
- 3) Slogans/Taglines
 “The World Leader in Oral Care Probiotics”

EXHIBIT D

TRADE SECRETS

- 1) Manufacturing and composition secrets pertaining to the ProBiora3 Business (as defined in the Asset Purchase Agreement)**
- 2) Test data pertaining to the ProBiora3 Business (as defined in the Asset Purchase Agreement)**
- 2) Customer and contact lists pertaining to the ProBiora3 Business (as defined in the Asset Purchase Agreement)**
- 3) Correspondence with consumers, researchers, FDA, patent and other attorneys pertaining to the ProBiora3 Business (as defined in the Asset Purchase Agreement)**

EXHIBIT E

MISCELLANEOUS INTELLECTUAL PROPERTY

<u>Domains</u>	<u>Exp Date</u>	<u>Registrant</u>
BUYEVORAPLUS.COM	11/06/16	ONI Biopharma Inc.
BUYEVORAPRO.COM	07/24/17	Oragenics, Inc.
DENTALPROBIOTICS.COM	12/08/16	ONI Biopharma Inc.
EVORAKIDS.COM	07/09/16	Private registration – Domains by Proxy
EVORAKIDS.NET	07/09/16	Oragenics, Inc.
EVORAKIDS.ORG	07/09/16	Oragenics, Inc.
EVORAORALCARE.COM	07/23/16	ONI Biopharma Inc.
EVORAORALPROBIOTICS.COM	04/22/17	Oragenics, Inc.
EVORAPET.COM	07/09/16	Private registration – Domains by Proxy
EVORAPET.NET	07/09/16	Private registration – Domains by Proxy
EVORAPET.ORG	07/09/16	Private registration – Domains by Proxy
EVORAPETOFFER.COM	07/09/16	Oragenics, Inc.
EVORAPLUS.COM	07/18/16	Private registration – Domains by Proxy
EVORAPLUS.NET	07/18/16	Private registration – Domains by Proxy
EVORAPLUS.ORG	07/18/16	Private registration – Domains by Proxy
EVORAPLUSNOW.COM	02/10/17	ONI Biopharma Inc.
EVORAPLUSSTORE.COM	02/10/17	ONI Biopharma Inc.
EVORAPLUSTODAY.COM	02/10/17	ONI Biopharma Inc.
EVORAPRO.COM	07/09/16	Private registration – Domains by Proxy
EVORAPRO.NET	07/09/16	Oragenics, Inc.
EVORAPRO.ORG	07/09/16	Private registration – Domains by Proxy
EVORAPROBIOTICS.COM	03/05/17	Oragenics, Inc.
FOREVORAPLUS.COM	09/24/16	ONI Biopharma Inc.
ORALPROBIOTICS.COM	12/08/16	ONI Biopharma Inc.
ORDEREVORAPLUS.COM	11/25/16	ONI Biopharma Inc.
PROBIOA3.COM	12/08/16	ONI Biopharma Inc.
YOUREVORAPLUS.COM	07/23/16	ONI Biopharma Inc.